TORC News and Press, resTORbio Inc. From 11/15/19

Gainers:  Akerna (NASDAQ: KERN ) +47% . More news on: Akerna Corp., Mmtec, Inc., Melinta Therapeutics, Inc., Stocks on the move, Read more ...

ResTORbio (NASDAQ: TORC )  -78%  after lead candidate flunks study. More news on: resTORbio, Inc., Tonix Pharmaceuticals Holding Corp., Agile Therapeutics, Inc., Stocks on the move, Read more ...

Thinly traded micro cap resTORbio (NASDAQ: TORC ) plummets  74%  premarket on increased volume in reaction to its announcement that lead candidate RTB101 failed to achieve the primary endpoint in a Phase 3 clinical trial, PROTECTOR 1 , evaluating its ability to prevent clinicall...

-- Company stops further development of clinically symptomatic respiratory illness indication but continues development of RTB101 in other aging-related diseases, including Parkinson’s disease -- -- Company remains well funded with $117.3 million in cash, cash equivalents and m...

This article was selected to be shared with PRO+ subscribers - find out more here . Overview ResTORbio is a Boston, MA company that went public in January 2018. In the aging science community, the company has been closely watched and admired as they are the most mature company targeting...

resTORbio (NASDAQ: TORC ): Q3 GAAP EPS of -$0.68 misses by $0.14 . More news on: resTORbio, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Top-line data from PROTECTOR 1 study expected by early first quarter of 2020 RTB101 Phase 2b data demonstrating upregulation of innate antiviral immunity presented at IDWeek ™ 2019 BOSTON, Nov. 05, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage bi...

WALTHAM, Mass., Oct. 08, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) (“AMAG”) today announced that it has entered into a settlement agreement with Caligan Partners LP (“Caligan”). As part of this agreement, the Board of Directors has appoin...

The following slide deck was published by resTORbio, Inc. in conjunction with this Read more ...

BOSTON, Oct. 02, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc., (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, will present new data today about RTB101, the company’s i...